Effects of low dose Methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial

Journal of Research in Medical Sciences

Volumn 16, Issue 4, 2011, Pages 457-462

  Ashtari, Fereshteh ^a   Savoj, Mohammad Reza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Interferon Beta; Methotrexate; Multiple Sclerosis

Indexed keywords

BETA1A INTERFERON; CINNOVEX; METHOTREXATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINGLE BLIND PROCEDURE;

EID: 79957566355     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2000; 13(3): 263-70.
2. Nicholas R, Chataway J. Multiple sclerosis. Clin Evid (Online). 2007 Aug 15; 2007. pii: 1202.
3. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6(10): 1-73.
4. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. West J Med 2000; 173(6): 398-402.
5. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005; 19(3): 239-52.
6. Miller A. Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med J 1997; 90(4): 367-75.
7. Myhr KM. Pharmacological treatment of multiple sclerosis. Tidsskr Nor Laegeforen 2010; 130(5): 490-2. [In Spanish].
8. Ransohoff RM. PML risk and natalizumab: more questions than answers. Lancet Neurol 2010; 9(3): 231-3.
9. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18(6): 379-96.
10. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79(1): 52-6.
11. O'Connor PW. Use of natalizumab in multiple sclerosis patients. Can J Neurol Sci 2010; 37(1): 98-104.
12. Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68(17): 2445-68.
13. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18(7): 985-9.
14. Warnke C, Meyer Zu HG, Hartung HP, Stuve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2009; 5: 333-40.
15. Zaffaroni M, Ghezzi A, Comi G. Intensive immunosuppression in multiple sclerosis. Neurol Sci 2006; 27(Suppl 1): S13-7.
16. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs. Neurology 1996; 47(5): 1153-7.
17. Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci 2001; 22(2): 209-10.
18. Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006; 12(4): 507-10.
19. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114(2): 154-63.
20. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 2004; 63(12 Suppl 6): S41-6.
21. Hommes OR, Weiner HL. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler 2002; 8(2): 139-41.
22. Fernandez O, Fernandez V, De Ramon E. Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci 2004; 223(1): 29-34.
23. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry 2001; 70(5): 574-9.
24. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005; 19(5): 369-76.
25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3): 227-31.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
27. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Schwetz KM, Fischer, J et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37(1): 30-40.
28. Bernatsky S, Ehrmann FD. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging 2008; 25(10): 879-84.
29. Florea A, Job-Deslandre C. [Rheumatoid arthritis and pregnancy]. Presse Med 2008; 37(11): 1644-51.
30. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59(8): 1074-81.
31. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993; 56(11): 1217-8.
32. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58(2): 314-7.
33. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24(3): 511-4.
34. McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc Natl Acad Sci U S A 2004; 101(Suppl 2): 14627-30.
35. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45(6 Suppl 6): S11-5.
36. Cua DJ, Hinton DR, Stohlman SA. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J Immunol 1995; 155(8): 4052-9.
37. Weiner HL, Friedman A, Miller A, Khoury SJ, Al Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809-37.
38. Zhang GX, Xu H, Kishi M, Calida D, Rostami A. The role of IL-12 in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J Immunol 2002; 168(5): 2501-7.
39. Zhang GX, Yu S, Li Y, Ventura ES, Gran B, Rostami A. A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 161(1-2): 101-12.